Risk for PML in Multiple Sclerosis Predicted With Anti-JCV Antibody Index
While an efficacious treatment for relapsing MS, natalizumab is associated with risk of developing progressive multifocal leukoencephalopathy.
The 2017 revision takes aim at better differentiating relapsing-remitting and primary-progressive forms of multiple sclerosis.
Diet quality is associated with disability and symptom severity in multiple sclerosis patients.
Investigators believe this is the largest study on the association between multiple sclerosis and epilepsy.